Treatment for Hodgkin's lymphoma has improved significantly since the ABVD chemotherapeutic combination was invented over 30 years ago. Despite using the same ABVD regimen in most patients treated first line, we now have a much better understanding of disease biology, late side effects of therapy and have moved towards a personalised risk adapted approach. This approach promises to deliver low toxicities and high cure rates for lower risk patients while reserving aggressive regimens for those high-risk patients who really need it.